missing translation for 'onlineSavingsMsg'
Learn More
  1. Home
  2. Products
  3. Antibodies
  4. Primary Antibodies
  5. All Primary Antibodies
  6. 18199464

CAR/NR1I3 Antibody (OTI1C6), DyLight 350, Novus Biologicals™

Mouse Monoclonal Antibody

Brand:  Novus Biologicals NBP2-71525UV

Product Code. 18199464

  • € 751.00 / 0.10mL

Please to purchase this item. Need a web account? Register with us today!

This item is not returnable. View return policy

Description

Description

CAR/NR1I3 Monoclonal specifically detects CAR/NR1I3 in Human samples. It is validated for Western Blot, Immunohistochemistry.
TRUSTED_SUSTAINABILITY
Specifications

Specifications

CAR/NR1I3
Monoclonal
DyLight 350
50mM Sodium Borate with 0.05% Sodium Azide
NR1I3
Recombinant protein fragment corresponding to amino acids 1-236 of human CAR/NR1I3 (NP_001070950) produced in E.coli.
0.1 mL
Primary
Human
IgG1
Western Blot, Immunohistochemistry
OTI1C6
Western Blot, Immunohistochemistry
CARCAR1, Constitutive activator of retinoid response, constitutive active receptor, Constitutive active response, Constitutive androstane receptor, MB67, MGC150433, MGC97144, MGC97209, nuclear receptor subfamily 1 group I member 3, nuclear receptor subfamily 1, group I, member 3, orphan nuclear hormone receptor, Orphan nuclear receptor MB67
Mouse
Affinity Purified
Lipid and Metabolism
9970.0
Store at 4°C in the dark.
Product Suggestions

Product Suggestions

Videos
SDS
Documents

Documents

Certificates
Promotions

Promotions

Product Content Correction

Your input is important to us. Please complete this form to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Thank You! Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.